BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23539813)

  • 21. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.
    Bacchus S; O'Mara N; Manley H; Fishbane S
    Ann Pharmacother; 2009 Nov; 43(11):1857-66. PubMed ID: 19826095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The significance of erythropoietin for nephrology].
    Watzinger U; Peer G; Barnas U; Mayer G; Luger A; Kovarik J; Graf H
    Wien Klin Wochenschr; 1990 Mar; 102(5):125-30. PubMed ID: 2181782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin in predialysis patients.
    Lim VS
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):34-7. PubMed ID: 1928077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of anaemia in CAPD patients with recombinant human erythropoietin.
    Ramello A; Malcangi U; Bruno M; Perosa P; Reina E; Rizzuto A; Nasini MG; Carozzi S
    Adv Perit Dial; 1990; 6():308-11. PubMed ID: 1982834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 29. [Iron stores in patients with chronic kidney failure treated with recombinant human erythropoietin].
    Cermák J; Gregora E; Lachmanová J; Brabec V
    Vnitr Lek; 1994 Mar; 40(3):174-8. PubMed ID: 8184571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron supplementation in renal anemia.
    Fishbane S
    Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Side effects of erythropoietin therapy.
    Bennett WM
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):84-6. PubMed ID: 1928085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant erythropoietin for the anemia of chronic renal failure.
    Ahmad R; Hand M
    N Engl J Med; 1987 Jul; 317(3):169-70. PubMed ID: 3600706
    [No Abstract]   [Full Text] [Related]  

  • 33. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
    Watson A
    J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin 1997: a brief update.
    Gahl GM; Eckardt KU
    Perit Dial Int; 1997; 17 Suppl 2():S84-90. PubMed ID: 9163805
    [No Abstract]   [Full Text] [Related]  

  • 35. Anemia management protocols and epoetin alfa administration: an algorithm approach. Case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2002 Jun; 29(3):297-300. PubMed ID: 12164081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
    Eschbach JW
    Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Erythropoietin, a milestone in the history of nephrology].
    Uehlinger DE; Frey FJ
    Ther Umsch; 1995 Oct; 52(10):672-7. PubMed ID: 7482378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of recombinant human erythropoietin on erythrocyte lines in patients with anemia and chronic renal insufficiency].
    Marisavljević D; Djukanović Lj; Lezajić V
    Srp Arh Celok Lek; 1992; 120(9-10):281-5. PubMed ID: 1306020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Retardation of hemodialysis by recombinant human erythropoietin in patients with chronic kidney disease].
    Kato F; Takeuchi N; Takenoshita E; Yuasa J; Isaka S; Fujii T; Suzuki S; Irie Y; Ogawa M; Ueda S
    Nihon Jinzo Gakkai Shi; 2010; 52(1):58-65. PubMed ID: 20166543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.